Contrast-enhanced CT radiomics for preoperative prediction of stage in epithelial ovarian cancer: a multicenter study
Ontology highlight
ABSTRACT:
SUBMITTER: Leng Y
PROVIDER: S-EPMC10916071 | biostudies-literature | 2024 Jan
REPOSITORIES: biostudies-literature
Similar Datasets
Project description:BackgroundMicrovascular invasion (MVI) has been shown to be closely associated with postoperative recurrence and metastasis in patients with intrahepatic cholangiocarcinoma (ICC). We aimed to develop a radiomics prediction model based on contrast-enhanced CT (CECT) to distinguish MVI in patients with mass-forming ICC.Methods157 patients were included and randomly divided into training (n=110) and test (n=47) datasets. Radiomic signatures were built based on the recursive feature elimination support vector machine (Rfe-SVM) algorithm. Significant clinical-radiologic factors were screened, and a clinical model was built by multivariate logistic regression. A nomogram was developed by integrating radiomics signature and the significant clinical risk factors.ResultsThe portal phase image radiomics signature with 6 features was constructed and provided an area under the receiver operating characteristic curve (AUC) of 0.804 in the training and 0.769 in the test datasets. Three significant predictors, including satellite nodules (odds ratio [OR]=13.73), arterial hypo-enhancement (OR=4.31), and tumor contour (OR=4.99), were identified by multivariate analysis. The clinical model using these predictors exhibited an AUC of 0.822 in the training and 0.756 in the test datasets. The nomogram combining significant clinical factors and radiomics signature achieved satisfactory prediction efficacy, showing an AUC of 0.886 in the training and 0.80 in the test datasets.ConclusionsBoth CECT radiomics analysis and radiologic factors have the potential for MVI prediction in mass-forming ICC patients. The nomogram can further improve the prediction efficacy.
| S-EPMC8640186 | biostudies-literature
Project description:BackgroundTo develop and validate a dual-phase contrast-enhanced computed tomography (CT)-based intratumoral and peritumoral radiomics for the prediction of lymphovascular invasion (LVI) in patients with gastric cancer.MethodThree hundred and eighty-three patients with gastric cancer (training cohort, 269 patients; test cohort, 114 patients) were retrospectively enrolled between January 2017 and June 2023. Radiomics features were extracted from the intratumoral volume (ITV) and peritumoral volume (PTV) on CT images at arterial phase (AP) and venous phase (VP), and selected by the least absolute shrinkage and selection operator. Radiomics models were constructed by logistic regression. The clinical-radiomics combined model incorporating the most predictive radiomics signature and clinical risk factors were developed with multivariate analysis. Receiver operating characteristic (ROC) curves were used to evaluate the prediction performance of models.ResultsClinical model comprised of three clinical risk factors including tumor differentiation, CT-reported lymph node metastasis status and CT-TNM staging showed good performance with an area under the ROC curve (AUC) of 0.804 and 0.825 in the training and test cohort, respectively. Compared with the other radiomics models, dual-phase (AP + VP) CT-based ITV + PTV radiomics model presented superior AUC of 0.844 and 0.835 in the training and test cohort, respectively. Clinical-radiomics combined model further improved the discriminatory performance (AUC, 0.903) in the training and test cohort (AUC, 0.901). Decision curve analysis confirmed the net benefit of clinical-radiomics combined model. Subgroup analyses showed that the clinical-radiomics nomogram showed the best performance with an AUC of 0.879 and 0.883 for predicting LVI in T1-T2 and T3-T4 gastric cancer compared with the clinical model and the ITV + PTV-AP + VP radiomics model, respectively.ConclusionsClinical-radiomics combined model integrating clinical risk factors and dual-phase contrast-enhanced CT-based intratumoral and peritumoral radiomics signatures provided favorable performance for predicting LVI in gastric cancer.
| S-EPMC11812222 | biostudies-literature
Project description:BackgroundThis study aimed to develop and validate 2-Dimensional (2D) and 3-Dimensional (3D) radiomics signatures based on contrast-enhanced computed tomography (CECT) images for preoperative prediction of the thymic epithelial tumors (TETs) risk and compare the predictive performance with conventional CT features.Patients and methods149 TET patients were retrospectively enrolled from January 2016 to December 2018, and divided into high-risk group (B2/B3/TCs, n = 103) and low-risk group (A/AB/B1, n = 46). All patients were randomly assigned into the training (n = 104) and testing (n = 45) set. 14 conventional CT features were collected, and 396 radiomic features were extracted from 2D and 3D CECT images, respectively. Three models including conventional, 2D radiomics and 3D radiomics model were established using multivariate logistic regression analysis. The discriminative performances of the models were demonstrated by receiver operating characteristic (ROC) curves.ResultsIn the conventional model, area under the curves (AUCs) in the training and validation sets were 0.863 and 0.853, sensitivity was 78% and 55%, and specificity was 88% and 100%, respectively. The 2D model yielded AUCs of 0.854 and 0.834, sensitivity of 86% and 77%, and specificity of 72% and 86% in the training and validation sets. The 3D model revealed AUC of 0.902 and 0.906, sensitivity of 75% and 68%, and specificity of 94% and 100% in the training and validation sets.ConclusionsRadiomics signatures based on 3D images could distinguish high-risk from low-risk TETs and provide complementary diagnostic information.
| S-EPMC11867572 | biostudies-literature
Project description:ObjectiveTo determine whether intratumoral and peritumoral radiomics derived from dual-phase contrast-enhanced CT imaging could predict lymph node metastasis (LNM) in gastric cancer.MethodsPatients with gastric cancer from January 2017 to January 2022 were retrospectively collected and were randomly divided into training cohort (n = 287) and test cohort (n = 121) with a ratio of 7: 3. Clinical features and traditional radiological features were analyzed to construct clinical model. Radiomics features based on intratumoral (ITV) and peritumoral volumetric (PTV) regions of the tumor were extracted and screened to construct radiomics models. Clinical-radiomics combined model was constructed by the most predictive radiomics features and clinical independent predictors. The correlation between LNM predicted by the best model and 2-year disease-free survival (DFS) was evaluated by the Kaplan-Meier analysis.ResultsCT-LNM and CT-T stage were independent predictors of LNM. Compared with other radiomics models, ITV + PTV on atrial and venous phase (ITV + PTV-AP + VP) radiomics model presented moderate AUCs of 0.679 and 0.670 in the training cohort and validation cohort, respectively. Among the models, clinical-radiomics combined model achieved the highest AUC of 0.894 and 0.872 in the training and test cohorts, and 0.744 and 0.784 in the T1-2 and T3-4 subgroups, respectively. Clinical-radiomics combined model based LNM could stratify patients into high-risk and low-risk groups, and 2-year DFS of high-risk group was significantly lower than that of low-risk group (p < 0.001).ConclusionClinical-radiomics combined model integrating CT-LNM, CT-T stage, and ITV-PTV-AP + VP radiomics features could predict LNM, and this combined model based LNM was associated with 2-year DFS.
| S-EPMC11869644 | biostudies-literature
Project description:ObjectivesTo identify radiomic features extracted from ultrasound images and to develop and externally validate a comprehensive model that combines clinical data with ultrasound radiomics features to predict the residual tumor status in patients with advanced epithelial ovarian cancer (OC).MethodsThe study included 112 patients with advanced epithelial OC who underwent preoperative transvaginal ultrasound. Of these, 78 patients were assigned to the development cohort and 34 to the external validation cohort. Tumor contours were manually delineated as regions of interest (ROI) on the ultrasound images, and radiomic features were extracted. The final set of variables was identified using LASSO (least absolute shrinkage and selection operator) regression. Clinical features were also collected and incorporated into the model. A combination model integrating ultrasound radiomics and clinical variables was developed and externally validated. The performance of the predictive models was assessed.ResultsA total of 1,561 radiomic features and 18 clinical features were extracted. The final model included 10 significant ultrasound radiomic variables and 4 clinical features. The comprehensive model outperformed models based on either clinical or radiomic features alone, achieving an accuracy of 0.84, a sensitivity of 0.80, a specificity of 0.75, a precision of 0.88, a positive predictive value of 0.81, a negative predictive value of 0.86, an F1-score of 0.78, and an AUC of 0.82 in the external validation set.ConclusionsThe comprehensive model, which integrated clinical and ultrasound radiomic features, exhibited strong performance and generalizability in preoperatively identifying patients likely to achieve complete resection of all visible disease.
| S-EPMC11832395 | biostudies-literature
Project description:To validate a contrast-enhanced CT (CECT)-based radiomics model (RM) for differentiating various risk subgroups of thymic epithelial tumors (TETs). A retrospective study was performed on 164 patients with TETs who underwent CECT scans before treatment. A total of 130 patients (approximately 79%, from 2012 to 2018) were designated as the training set, and 34 patients (approximately 21%, from 2019 to 2021) were designated as the testing set. The analysis of variance and least absolute shrinkage and selection operator algorithm methods were used to select the radiomics features. A logistic regression classifier was constructed to identify various subgroups of TETs. The predictive performance of RMs was evaluated based on receiver operating characteristic (ROC) curve analyses. Two RMs included 16 and 13 radiomics features to identify three risk subgroups of traditional risk grouping [low-risk thymomas (LRT: Types A, AB and B1), high-risk thymomas (HRT: Types B2 and B3), thymic carcinoma (TC)] and improved risk grouping [LRT* (Types A and AB), HRT* (Types B1, B2 and B3), TC], respectively. For traditional risk grouping, the areas under the ROC curves (AUCs) of LRT, HRT, and TC were 0.795, 0.851, and 0.860, respectively, the accuracy was 0.65 in the training set, the AUCs were 0.621, 0.754, and 0.500, respectively, and the accuracy was 0.47 in the testing set. For improved risk grouping, the AUCs of LRT*, HRT*, and TC were 0.855, 0.862, and 0.869, respectively, and the accuracy was 0.72 in the training set; the AUCs were 0.778, 0.716, and 0.879, respectively, and the accuracy was 0.62 in the testing set. CECT-based RMs help to differentiate three risk subgroups of TETs, and RM established according to improved risk grouping performed better than traditional risk grouping.
| S-EPMC8898532 | biostudies-literature
Project description:BackgroundThe present study constructed and validated the use of contrast-enhanced computed tomography (CT)-based radiomics to preoperatively predict microvascular invasion (MVI) status (positive vs negative) and risk (low vs high) in patients with hepatocellular carcinoma (HCC).MethodsWe enrolled 637 patients from two independent institutions. Patients from Institution I were randomly divided into a training cohort of 451 patients and a test cohort of 111 patients. Patients from Institution II served as an independent validation set. The LASSO algorithm was used for the selection of 798 radiomics features. Two classifiers for predicting MVI status and MVI risk were developed using multivariable logistic regression. We also performed a survival analysis to investigate the potentially prognostic value of the proposed MVI classifiers.ResultsThe developed radiomics signature predicted MVI status with an area under the receiver operating characteristic curve (AUC) of .780, .776, and .743 in the training, test, and independent validation cohorts, respectively. The final MVI status classifier that integrated two clinical factors (age and α-fetoprotein level) achieved AUC of .806, .803, and .796 in the training, test, and independent validation cohorts, respectively. For MVI risk stratification, the AUCs of the radiomics signature were .746, .664, and .700 in the training, test, and independent validation cohorts, respectively, and the AUCs of the final MVI risk classifier-integrated clinical stage were .783, .778, and .740, respectively. Survival analysis showed that our MVI status classifier significantly stratified patients for short overall survival or early tumor recurrence.ConclusionsOur CT radiomics-based models were able to predict MVI status and MVI risk of HCC and might serve as a reliable preoperative evaluation tool.
| S-EPMC7403665 | biostudies-literature
Project description:Background/Objectives: To develop a nomogram for the preoperative prediction of pathologic T3a (pT3a) upstaging in patients with clinical T1(cT1) renal cell carcinoma (RCC). Methods: A total of 169 cT1 patients with RCC with preoperative contrast-enhanced CT (CECT) and clinical data were enrolled in this study. Afterwards, the sample was split randomly into training and testing sets in a 7:3 ratio. Radiomics features were extracted and selected from the whole primary tumor on CECT images to develop radiomics signatures. The nomogram was constructed using the obtained radiomics signature and clinical risk factors. The predictive performance of different models was evaluated and visualized using receiver operator characteristic (ROC) curves. Results: In total, 26 radiomics features were selected for the radiomics signature construction. The radiomics signature yielded area under the curve (AUC) values of 0.945 and 0.873 in the training and testing sets, respectively. The nomogram integrating radiomics signature and predictive clinical factors, including tumor size and neutrophil-lymphocyte ratio (NLR), achieved higher predictive performance in the training [AUC, 0.958; 95% confidence interval (CI): 0.921, 0.995] and testing (AUC, 0.913; 95% CI: 0.814, 1.000) sets. Good calibration was achieved for the nomogram in both the training and testing sets (Brier score = 0.082 and 0.098). Decision curve analysis (DCA) demonstrated that the nomogram was clinically useful in predicting pT3a upstaging, with a corresponding net benefit of 0.378. Conclusions: The proposed nomogram can preoperatively predict pT3a upstaging in cT1 RCC and serve as a non-invasive imaging marker to guide individualized treatment.
| S-EPMC11854503 | biostudies-literature
Project description:BackgroundWe evaluated the ability of radiomics based on intratumoral and peritumoral regions on preoperative gastric cancer (GC) contrast-enhanced CT imaging to predict disease-free survival (DFS) and chemotherapy response in stage II/III GC.MethodsThis study enrolled of 739 consecutive stage II/III GC patients. Within the intratumoral and peritumoral regions of CT images, 584 total radiomic features were computed at the portal venous-phase. A radiomics signature (RS) was generated by using support vector machine (SVM) based methods. Univariate and multivariate Cox proportional hazards models and Kaplan-Meier analysis were used to determine the association of the RS and clinicopathological variables with DFS. A radiomics nomogram combining the radiomics signature and clinicopathological findings was constructed for individualized DFS estimation.ResultsThe radiomics signature consisted of 26 features and was significantly associated with DFS in both the training and validation sets (both P<0.0001). Multivariate analysis showed that the RS was an independent predictor of DFS. The signature had a higher predictive accuracy than TNM stage and single radiomics features and clinicopathological factors. Further analysis showed that stage II/III patients with high scores were more likely to benefit from adjuvant chemotherapy.ConclusionThe newly developed radiomics signature was a powerful predictor of DFS in GC, and it may predict which patients with stage II and III GC benefit from chemotherapy.
| S-EPMC7794018 | biostudies-literature
Project description:ObjectivesTo investigate the value of contrast-enhanced computer tomography (CT)-based on radiomics in discriminating high-grade and low-grade hepatocellular carcinoma (HCC) before surgery.MethodsThe retrospective study including 161 consecutive subjects with HCC which was approved by the institutional review board, and the patients were divided into a training group (n = 112) and test group (n = 49) from January 2013 to January 2018. The least absolute shrinkage and selection operator (LASSO) was used to select the most valuable features to build a support vector machine (SVM) model. The performance of the predictive model was evaluated using the area under the curve (AUC), accuracy, sensitivity, and specificity.ResultsThe SVM model showed an acceptable ability to differentiate high-grade from low-grade HCC, with an AUC of 0.904 in the training dataset and 0.937 in the test dataset, accuracy (92.2% versus 95.7%), sensitivity(82.5% versus 88.0%), and specificity (92.7% versus 95.8%), respectively.ConclusionThe machine learning-based radiomics reflects a better evaluating performance in differentiating HCC between low-grade and high-grade, which may contribute to personalized treatment.
| S-EPMC8212783 | biostudies-literature